Otros idiomas Zai Lab Limited

Acciones

ZLAB

US98887Q1040

Farmacéuticos

Tiempo real estimado Cboe BZX Otros sitios de cotización 20:03:15 18/11/2025			Variación 5 días	Varia. 1 de enero.
20,48 ^USD	-2,08 %		-6,77 %	-21,69 %

07/11	Zai Lab Limited, Q3 2025 Earnings Call, Nov 06, 2025
07/11	Pérdidas de Zai Lab se reducen en el tercer trimestre mientras los ingresos aumentan un 14%; las acciones caen un 8%	MT

Otros idiomas

Zai Lab : Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week	10/11
Zai Lab's Q3 Loss Narrows as Revenue Jumps 14%; Shares Fall 8%	07/11
Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	06/11
Zai Lab Q3 Loss Narrows, Revenue Rises; 2025 Revenue Outlook Revised	06/11
Earnings Flash (ZLAB) Zai Lab Posts Q3 Loss $0.33 per ADS, vs. FactSet Est of $0.29 Loss	06/11
Earnings Flash (ZLAB) Zai Lab Posts Q3 Revenue $116.1M, vs. FactSet Est of $141.7M	06/11
Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $116.1M, vs. FactSet Est of $141.7M	06/11
Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Loss of $0.33 per ADS	06/11
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates	06/11
Zai Lab Limited Revises Revenue Guidance for Full Year 2025	06/11
Zai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy	05/11
Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	05/11
Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	05/11
Zai Lab Announces Participation in Investor Conferences in November and December 2025	31/10
Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	30/10
Asian Equities Traded in the US as American Depositary Receipts End Week Higher in Friday Trading	24/10
Zai Lab : Zocilurtatug pelitecan (ZL 1310) AACR NCI EORTC 2025 Highlights	24/10
Zai Lab Says Potential Lung Cancer Treatment Shows High Response Rate in Updated Phase 1 Data	24/10
Zai Lab Limited Announces Updated Phase 1 Data for Zocilurtatug Pelitecan, Demonstrating Potential as First-In-Class/Best-In-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study	24/10
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study	24/10
Zai Lab Secures 300 Million Yuan Credit Line	17/10
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025	15/10
Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	14/10
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan ZL 1310 a Potential First in Class DLL3 Targeted ADC at 2025 AACR NCI EORTC Conference	14/10
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference	13/10

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Zai Lab Limited

Acciones

ZLAB

US98887Q1040

Farmacéuticos

Otros idiomas

Filtros